## **BIO-TECHNE CORP.**

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock



#### **Company Profile**

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

## Financial figures, Fiscal year: from 01.07. to 30.06.

	20	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity	
Current assets	621,482,000		605,556,000		510,606,000		
Common stock capital		1,576,000		392,000		390,000	
Fixed assets	2,112,233,000		1,765,472,000		1,839,234,000		
Equity capital of a company		1,966,516,000		1,701,011,000		1,571,234,000	
Cash and cash equivalents	180,571,000		172,567,000		199,091,000		
Accrued liabilities		0		0		0	
Other assets	-		-		-		
Current liabilities		128,509,000		176,018,000		152,284,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		638,690,000		493,999,000		626,322,000	
Different income		-		-		-	
Other liabilities		10,919,000		17,239,000		49,862,000	
Total assets	2,733,715,000	2,733,715,000	2,371,028,000	2,371,028,000	2,349,840,000	2,349,840,000	

### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	3,050	3,000	2,600
Equity ratio	71.94%	71.71%	67.22%
Debt-equity ratio	39.01%	39.45%	48.77%

### Others

	2023	2022	2021
Tax Expense Rate	15.71%	12.70%	5.80%

# **BIO-TECHNE CORP.**

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	1,136,702,000	1,105,599,000	931,032,000
Net income	285,193,000	271,930,000	140,324,000
EBIT	321,433,756	292,347,206	156,393,487
Operating income before taxes	338,659,000	301,386,000	148,175,000
Cash Flow	254,393,000	325,272,000	352,164,000
Net interest income	-11,258,000	-16,867,000	-22,077,000
Research and development expenses	92,493,000	87,140,000	70,603,000
Income taxes	53,217,000	38,287,000	8,590,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	342,352	338,534	328,941

## **Board of Directors**

Members of Management Board		
Robert Baumgartner	Chairman of Board of Directors	
Alpna Seth	Member of Board of Directors	
Joseph Keegan	Member of Board of Directors	
Judith Klimovsky	Member of Board of Directors	
Randolph Steer	Member of Board of Directors	
Roeland Nusse	Member of Board of Directors	
Rupert Vessey	Member of Board of Directors	
Charles Kummeth	Member of Board of Directors	
John Higgins	Member of Board of Directors	
Julie Bushman	Member of Board of Directors	
Charles Kummeth	Chairman of Managing Board	
Brenda S. Everson	Member of Executive Committee	
Jim Hippel	Member of Executive Committee	
Kevin Smyth	Member of Executive Committee	